Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference
MONTREAL, Feb. 25, 2021 – Theratechnologies (NASDAQ: THTX) announced that its CEO, Paul Levesque, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MONTREAL, Feb. 25, 2021 – Theratechnologies (NASDAQ: THTX) announced that its CEO, Paul Levesque, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on demand from March 9 at 7:00 a.m. ET via the Company’s website and the virtual conference link. It will remain archived for 90 days. Theratechnologies focuses on innovative therapies that address unmet medical needs, reinforcing its commitment to advancing biopharmaceutical solutions.
Details
News Market Reaction – THTX
The recorded move for THTX in the trading session of this news was +3.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually March 9 – 10, 2021.
The presentation will be available on demand beginning Tuesday, March 9, 2021 at 7:00 a.m. ET on the ‘News’ section of the Company’s website or via the virtual conference link, and will be archived for 90 days.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
For media inquiries:
Denis Boucher
Vice-President, Communications and Corporate Affairs
514-336-7800
For investor inquiries:
Leah Gibson
Senior Director, Investor Relations
lgibson@theratech.com
617-356-1009
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.